Two Accepted Abstracts at AACR 2024 Explore Clinical Applications of TK1 Biomarker

We are happy to announce that two abstracts on clinical applications of AroCell TK 210 ELISA have been accepted for poster presentations at the American Association of Cancer Research 2024 (AACR 2024) held from April 5 to 10 in San Diego, USA.

One of the abstracts is on the prognostic value of serum TK1 protein levels in Diffuse large B cell lymphoma (DLBCL) patients treated with a combination therapy called R-CHOP. Below is the link for the full abstract:
https://www.abstractsonline.com/pp8/#/1/20272/presentation/1871

The other abstract is on serum TK1 protein concentrations as a predictive marker for castration resistance in metastatic prostate cancer. Below is the link for the abstract:
https://www.abstractsonline.com/pp8/#/1/20272/presentation/11593

Contacts

Anders Hultman, CEO
Phone: +46 (0) 8 799 67 50
E-mail: anders.hultman@arocell.com

About AroCell

AroCell AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare, and established in various markets. In oncology, AroCell uses various biomarkers, TK1, and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. AroCell's product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. AroCell (AROC) is listed on Nasdaq First North Growth Market with Redeye AB as company's Certified Adviser. For more information; www.arocell.com

Attachments

Two Accepted Abstracts at AACR 2024 Explore Clinical Applications of TK1 Biomarker